Abstract:The aim of the study is to compare Roux-en-Y gastric bypass (RYGB) surgery versus medical treatment for type 2 diabetes mellitus (T2DM) in obese patients.Bariatric surgery can achieve remission of T2DM in obese patients. RYGB surgery has been performed as one of the most common surgical treatment options for obese patients with T2DM, but the efficacy of RYGB surgery comparing with medical treatment alone has not been conclusively determined.A systematic literature search identified randomized controlled trials (RCTs) evaluating RYGB surgery versus medical treatment for T2DM in obese patients was conducted in PubMed, Embase, Cochrane Database, and Cochrane Clinical Trials Registry. This systematic review and meta-analysis were performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The primary outcome was T2DM remission. Additional analyses comprised hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body mass index (BMI), waist circumference, serum lipid level, blood pressure, medication use, and adverse events. Random-effects meta-analyses were calculated and presented as weighted odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CI).Six RCTs concerning 410 total obese T2DM patients were included. Follow-up ranged from 12 to 60 months. RYGB surgery was associated with a higher T2DM remission rate (OR: 76.37, 95% CI: 20.70-281.73, P < 0.001) and serum level of high-density lipoprotein cholesterol (MD: 0.24 mmol/L, 95% CI 0.18-0.30 mmol/L, P < 0.001) than medical treatment alone. HbA1c (MD: -1.25%, 95% CI: -1.88% to -0.63%, P < 0.001), BMI (MD: -6.54 kg/m, 95% CI: -9.28 to -3.80 kg/m, P < 0.001), waist circumference (MD: -15.60 cm, 95% CI: -18.21 to -13.00 cm, P < 0.001), triglyceride (MD: -0.87 mmol/L, 95% CI: -1.17 to -0.57 mmol/L, P < 0.001), low-density lipoprotein cholesterol (MD: -0.32 mmol/L, 95% CI: -0.62 to -0.02 mmol/L, P = 0.04), systolic blood pressure (MD: -2.83 mm Hg, 95% CI: -4.88 to -0.78 mm Hg, P < 0.01) were lower after RYGB surgery. However, FPG (MD: -1.58 mmol/L, 95% CI: -3.58 to 0.41 mmol/L, P = 0.12), total cholesterol (MD: -0.40 mmol/L, 95% CI: -0.92 to 0.12 mmol/L, P = 0.13), and diastolic blood pressure (MD: 0.28 mm Hg, 95% CI: -1.89 to 2.45 mm Hg, P = 0.80) were not significantly different between the 2 treatment groups. The medicine use and quality of life were solely improved in the surgical group. Nutritional deficiencies and anemia were noted more frequently in the RYGB group.RYGB surgery is superior to medical treatment for short- to medium-term remission of T2DM, improvement of metabolic condition, and cardiovascular risk factors. Further RCTs should address the safety and long-term benefits of RYGB surgery on obese patients with T2DM.

Cost-Utility of Laparoscopic Roux-en-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes and Obesity with a BMI ≥ 27.5 Kg/m2: a Multi-Center Study with a 4-Year Follow-Up of Surgical Cohort

Metabolic Effects and Safety of Roux‐en‐Y Gastric Bypass Surgery Vs. Conventional Medication in Obese Chinese Patients with Type 2 Diabetes

Analysis of long-term outcome of modified gastric bypass for type 2 diabetes mellitus in Chinese patients

Roux-en-Y Gastric Bypass for T2D Treatment in Chinese Patients with Low BMI: 5-Year Outcomes

Effect of Roux-en-Y Gastric Bypass on Remission of T2D: Medium-Term Follow-up in Chinese Patients with Different BMI Obesity Class

Effect of Roux-En-Y Gastric Bypass on the Remission of Type 2 Diabetes: A 3-Year Study in Chinese Patients with A Bmi < 30 Kg/M(2)

Cost-Effectiveness of Laparoscopic Sleeve Gastrectomy for Chinese Patients

Roux-en-Y gastric bypass surgery for non obese type 2 diabetes patients

Roux-en-Y Gastric Bypass Versus Medical Treatment for Type 2 Diabetes Mellitus in Obese Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Effectiveness and Safety of Laparoscopic Roux-en-Y Gastric Bypass for the Treatment of Type 2 Diabetes Mellitus

Comparison of Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy in Obese Patients with Type 2 Diabetes

Laparoscopic Roux-en-Y Gastric Bypass for Type 2 Diabetes Mellitus Patients in Various Obesity Degree

A Randomized Clinical Trial of Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy for the Treatment of Morbid Obesity in China: a 5-Year Outcome

Long-term outcomes of Roux-en-Y gastric bypass versus medical therapy for patients with type 2 diabetes: a meta-analysis of randomized controlled trials

Comparison of health care costs following sleeve gastrectomy versus Roux‐en‐Y gastric bypass among patients with type 2 diabetes

Metabolic Surgery for the Treatment of Type 2 Diabetes Mellitus in China-Five-Year Outcomes from a Prospective Multicenter Study

Is Roux-en-Y gastric bypass advantageous?—surgical outcomes in obese patients with type-2 diabetes after gastric bypass versus sleeve gastrectomy, a matched retrospective study

Chenodeoxycholic Acid As a Potential Prognostic Marker for Roux-en-Y Gastric Bypass in Chinese Obese Patients.

Comparative evaluation of early diabetic outcomes in southeast asian patients with type 2 diabetes mellitus undergoing Roux-en-Y gastric bypass (RYGB) versus sleeve gastrectomy (LSG)

Two-Year Results of Multicenter, Prospective Study of Metabolic Surgery in Obese Type 2 Diabetes Mellitus Subjects in China

Efficacy of laparoscopic Roux-en-Y gastric bypass in the treatment of morbid obesity complicated with type 2 diabetes mellitus.